Welcome to our dedicated page for Journey Medical SEC filings (Ticker: DERM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Journey Medical Corporation (DERM) SEC filings page on Stock Titan provides access to the company’s public regulatory documents as filed with the U.S. Securities and Exchange Commission. Journey Medical is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription pharmaceutical products for dermatological conditions, with its common stock listed on The Nasdaq Capital Market under the symbol DERM and registered pursuant to Section 12(b) of the Securities Exchange Act of 1934.
Through its SEC filings, investors can review Journey Medical’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe its dermatology-focused business, portfolio of eight branded FDA-approved prescription drugs, risk factors, and financial statements. Current reports on Form 8-K provide updates on material events, including quarterly financial results, amendments to credit agreements, at-the-market equity sales programs, changes to the company’s certificate of incorporation, index inclusion announcements, and disclosures related to the commercialization and pharmacy benefit coverage of Emrosi (DFD-29) for inflammatory lesions of rosacea in adults.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as Journey Medical’s revenue composition, term loan arrangements, equity issuance programs, governance changes, and other significant disclosures. Real-time updates from the EDGAR system ensure that new 8-Ks, 10-Qs, and 10-Ks are reflected promptly, while access to exhibits and related materials allows for deeper review when needed.
In addition, users can monitor forms that disclose capital markets and corporate actions referenced in Journey Medical’s filings. By combining original SEC documents with AI-generated explanations, this page is intended to make Journey Medical’s regulatory history and ongoing reporting more accessible to investors, analysts, and others researching DERM.
Journey Medical Corp ownership disclosure: Wasatch Advisors reports beneficial ownership of 2,133,370 shares, representing 10.0% of the common stock as reported 03/31/2026. The filing shows sole voting power for 1,979,366 shares and sole dispositive power for 2,133,370 shares.
Journey Medical Corporation outlines its dermatology-focused business in its annual report, highlighting a portfolio of eight FDA‑approved prescription products and several legacy brands. The company concentrates on acne, rosacea, hyperhidrosis, fungal infections, pruritus and wound care, selling mainly through specialty pharmacies and distributors in the U.S.
In 2024 the FDA approved Emrosi, a low‑dose oral minocycline for rosacea, which launched commercially in 2025 and is protected by patents through 2039. Journey also markets Qbrexza, Amzeeq, Zilxi and Accutane under multiple in‑license and acquisition agreements that include milestones and royalties.
The report emphasizes growth via additional product licenses and acquisitions, notes new out‑licensing deals in Asia, and describes reliance on third‑party manufacturers and partners. It also details extensive intellectual property, regulatory and healthcare compliance frameworks, and key risks such as generic competition, pricing pressure, and Fortress Biotech’s voting control.
Journey Medical Corporation reported full-year 2025 results with total revenues of $61.9 million, up from $56.1 million in 2024. Net loss narrowed to $11.4 million compared with $14.7 million a year earlier, and GAAP net loss per share improved to $0.47 from $0.72.
The company generated non-GAAP Adjusted EBITDA of $2.9 million, up from $0.8 million in 2024, reflecting higher product revenue and lower research and development spending. Cash and cash equivalents were $24.1 million as of December 31, 2025, compared with $20.3 million at year-end 2024.
Management highlighted the launch of Emrosi™, which generated $14.7 million in net revenues in 2025 after its early April launch, with approximately 53,000 prescriptions filled and payer access to over 100 million U.S. commercial lives.
Journey Medical Corporation is launching an at-the-market offering of up to 3,750,000 shares of common stock under a sales agreement with B. Riley Securities and Lake Street Capital. The shares may be sold from time to time on The Nasdaq Capital Market at prevailing prices, with the Agents receiving a 3.0% commission on gross proceeds and being deemed underwriters. If all shares were sold at a recent price of $7.27, the company illustrates potential gross proceeds of about $27.3 million and an increase in net tangible book value per share, but also immediate dilution of $6.49 per share to new investors. Journey plans to use any net proceeds for general corporate purposes, including working capital, research and development, licensing payments, sales and marketing, and capital expenditures. The company highlights that investors face dilution risk, stock price volatility from ongoing ATM sales, and that an independent auditor has raised substantial doubt about its ability to continue as a going concern.
Journey Medical Corporation has filed a shelf registration that allows it to offer up to $150,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time. The company can sell these securities in one or more offerings, separately or bundled in units, with specific terms and pricing to be detailed in future prospectus supplements. Net proceeds may be used for general corporate purposes, including working capital, research and development, licensing payments, sales and marketing, administrative expenses and capital expenditures. Journey is a commercial-stage pharmaceutical company focused on FDA-approved dermatology products, including the recently approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for inflammatory lesions of rosacea in adults. The company is controlled by Fortress Biotech through Class A Common Stock with majority voting power and is classified as both an emerging growth company and a smaller reporting company. The independent auditor’s report on the 2024 financial statements includes an explanatory paragraph noting recurring losses from operations that raise substantial doubt about Journey’s ability to continue as a going concern.
Journey Medical Corporation has filed a shelf registration that allows it to offer up to $150,000,000 of common stock, preferred stock, debt securities, warrants and units over time. Within this shelf, the company established an at‑the‑market program to sell up to 3,750,000 shares of common stock through B. Riley Securities and Lake Street Capital Markets, which will earn a 3.0% commission on gross proceeds. Shares will be issued at prevailing market prices on Nasdaq, where the stock trades under the symbol “DERM” and last closed at $7.27 on January 9, 2026.
Journey plans to use any proceeds for general corporate purposes, including working capital, research and development, sales and marketing, operating expenses, capital expenditures, and potential acquisitions or in‑licensing of additional dermatology products. The company is a commercial‑stage dermatology pharmaceutical business with eight FDA‑approved prescription products and a newly approved rosacea drug, Emrosi, and it remains an emerging growth and smaller reporting company controlled by Fortress Biotech. Its most recent audited financial statements include an auditor’s going concern explanatory paragraph citing recurring losses from operations.
Journey Medical reported Q3 2025 results. Total revenue was $17.631 million, up 21% year over year, with product revenue of $17.025 million. Net loss narrowed to $2.315 million (basic and diluted loss per share of $0.09).
Emrosi contributed $4.883 million as its U.S. launch scaled, while Qbrexza delivered $7.361 million. Accutane declined to $2.769 million amid competition. The company also recognized $0.606 million of other revenue from supplying Amzeeq to Cutia.
Cash and cash equivalents were $24.948 million and working capital was $16.7 million as of September 30, 2025. Year-to-date, the company raised $10.939 million via its ATM program (including $6.891 million in Q3). Term loan principal remained $25.0 million; effective interest was 14.47%.
On September 25, 2025, Journey amended its SWK Credit Facility, extending maturity to June 27, 2028 and lowering the revenue threshold for extending the interest-only period to $60.0 million on a trailing twelve-month basis. The company stated that, due to recurring and historical losses, substantial doubt exists about its ability to continue as a going concern.
Journey Medical Corporation furnished a press release providing a corporate update and its financial results for the three months ended September 30, 2025. The press release is included as Exhibit 99.1 to this report.
The information in this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” under the Exchange Act, and will not be incorporated by reference into Securities Act filings except as specifically referenced. The company’s common stock trades on the Nasdaq Capital Market under the symbol DERM.
Journey Medical Corporation entered into a Third Amendment to its Credit Agreement with SWK Funding LLC, updating the terms of its existing $25.0 million term loan, which has been fully drawn and is treated as a single Term Loan. The amendment extends the loan’s maturity date from December 27, 2027 to June 27, 2028, giving the company more time before final repayment is due.
Beginning in February 2026, the company must make quarterly principal payments equal to 7.5% of the funded Term Loan. However, if total revenue on a trailing twelve‑month basis exceeds $60.0 million as of December 31, 2025 (revised from $70.0 million), principal payments are deferred until February 2027, at which point quarterly payments increase to 10.0% of the funded amount (revised from 15.0%). These changes adjust how quickly the loan is repaid and link the timing and size of payments more closely to the company’s revenue performance.